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the proliferation of MM1S multiple
myeloma cells.
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Methylation of lysine residues on histone tail is a dy-
namic epigenetic modification that plays a key role in
chromatin structure and gene regulation. Members
of the KDM5 (also known as JARID1) sub-family are
2-oxoglutarate (2-OG) and Fe2+-dependent oxy-
genases acting as histone 3 lysine 4 trimethyl
(H3K4me3) demethylases, regulating proliferation,
stem cell self-renewal, and differentiation. Here we
present the characterization of KDOAM-25, an inhib-
itor of KDM5 enzymes. KDOAM-25 shows biochem-
ical half maximal inhibitory concentration values
of <100 nM for KDM5A-D in vitro, high selectivity to-
ward other 2-OG oxygenases sub-families, and no
off-target activity on a panel of 55 receptors and en-
zymes. In human cell assay systems, KDOAM-25 has
a half maximal effective concentration of50 mMand
good selectivity toward other demethylases. KDM5B
is overexpressed in multiple myeloma and negatively
correlatedwith the overall survival. Multiplemyeloma
MM1S cells treated with KDOAM-25 show increased
global H3K4 methylation at transcriptional start sites
and impaired proliferation.
INTRODUCTION
The site- and methylation state-specific modification of histone
lysyl residues differentially regulates transcription by providingCell Chemical Biology 24, 371–380, M
This is an open access article undunique interaction sites that bind to methyl-lysine recognition
(or ‘‘reader’’) domains (Ng et al., 2009). Genome-wide analyses
of tri- or di-methylated histone 3- lysine 4 (H3K4me3 or
H3K4me2) sites demonstrate that these histone marks are asso-
ciated with promoter regions and transcriptional start sites at
the 50 end of genes (ENCODE Project Consortium, 2012). Inter-
action of these di- or tri-methylated histone marks with the tran-
scription initiation factor TFIID (Lauberth et al., 2013), or with
chromatin remodeling complexes, leads to formation of a pre-
initiation complex that can be rapidly activated by further
recruitment of specific transcription factors (Chai et al., 2013,;
Tanny, 2014).
The dynamic interplay between chromatin methylation and
demethylation is catalyzed by distinct classes of enzymes. The
removal of methyl groups from histone lysine residues is
catalyzed by two classes of lysine (K) demethylases (KDMs)
with different co-factor and substrate dependencies: the flavine
adenine dinucleotide-dependentmonoamino oxidases (grouped
as the KDM1 sub-family) and the Fe(II) and 2-oxoglutarate
(2-OG)-dependent oxygenases that contain a conserved cata-
lytic Jumonji C domain ([JmjC] belonging to sub-families
KDM2- KDM7) (Johansson et al., 2014).
Members of the KDM5 sub-family of JmjC-KDMs are tran-
scriptional co-repressors, which specifically catalyze the
removal of all possible methylation states from lysine 4 of histone
H3 (H3K4me3/me2/me1), with highest activity found toward
H3K4me3. KDM5 enzymes are often found as components of
transcriptional complexes with repressors such as REST, his-
tone deacetylases, and histone methyl transferases (Pasini
et al., 2008). In mammals the KDM5 sub-family encompasses
four proteins, KDM5A (known as JARID1A or RBP2), KDM5B
(known as JARID1B or PLU1), KDM5C (JARID1C or SMCX),arch 16, 2017 ª 2017 The Authors. Published by Elsevier Ltd. 371
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X and Y chromosomes, respectively.
The KDM5 family and domain architecture is conserved from
yeast to humans, displaying a similar pattern with a Jumonji
N domain (JmjN), a DNA binding ARID domain (AT-rich interac-
tive domain), a catalytic JmjC, a C5HC2 zinc-finger motif located
C-terminally to the JmjC, a PLU-1 motif, as well as one to three
methyl-lysine or methyl-arginine binding plant homeodomains
(PHDs) denoted PHD-1, PHD-2, and PHD-3. It is conceivable
that these additional domains contribute critically to genomic
KDM5 target gene occupation, since PHD domains are able to
bind to modified lysine residues in a sequence-specific manner
(Horton et al., 2016; Johansson et al., 2016).
The KDM5 enzymes are suggested to play pivotal roles both
during normal development and in pathological conditions
such as cancer. KDM5A is ubiquitously expressed and involved
in the control of cell proliferation and differentiation, and linked to
several human cancers including acute myeloid leukemia (Wang
et al., 2009), hepatocellular carcinoma (Liang et al., 2013), gastric
cancer (Li et al., 2014), (Zeng et al., 2010), and lung cancer (Teng
et al., 2013;Wang et al., 2013). KDM5B plays an important role in
stem cell biology by blocking differentiation in embryonic and he-
matopoietic stem cells (Cellot et al., 2013; Dey et al., 2008).
Similar to KDM5A, elevated expression levels have been found
in various primary cancers including melanoma (Roesch et al.,
2010), breast (Barrett et al., 2002), testicular (Madsen et al.,
2003), and ovarian cancer (Wang et al., 2015). KDM5C plays a
role in neuronal development and shows highest expression in
neuronal tissues. Inactivating mutations have been associated
with X-linked intellectual disability (Santos-Reboucas et al.,
2011). The Y chromosome-encoded KDM5D is expressed in all
male tissues, and the protein has a suggested role in spermato-
genesis (Akimoto et al., 2008).
Chemical tool compounds complement biological target iden-
tification strategies such as gene editing or knock down, and
play important roles in dissecting the function of specific do-
mains in target biology. Although inhibitors have been reported
for JmjC-containing KDMs (Bavetsias et al., 2016; Gehling
et al., 2016; Horton et al., 2016; Itoh et al., 2015; McAllister
et al., 2016; Vinogradova et al., 2016; Westaway et al., 2016a,
2016b; Wu et al., 2016), most of the published compounds
have limitations such as lack of selectivity or cytotoxicity. Bavet-
sias et al. (2016) reported a new class of cell-active histone lysine
demethylase inhibitors. The compounds are based on a cell-
permeable pyridopyrimidinone scaffold. However, these com-
pounds do not show any selectivity between the KDM4 and
KDM5 families. Another cell-active pan-KDM inhibitor is the
pro-drug of IOX1 (Schiller et al., 2014), yet this compound is
affected by high cytotoxicity. All these limitations hamper the
use of these molecules as tool compounds in a cellular context.
Among the others, a recently reported KDM5A inhibitor (Liang
et al., 2016) is the most remarkable tool compound/pre-clinical
candidate for cancer therapy. This orally bioavailable pyrazolo-
pyrimidinone shows both high inhibitions of KDM5demethylases
on a TR-FRET biochemical assay and good activity in cell-based
assays, thus making this compound the best chemical tool re-
ported in the literature to date.
In this paper, we report the biochemical and molecular
genome-wide characterization of KDOAM-25, a new, selective,372 Cell Chemical Biology 24, 371–380, March 16, 2017and cell-active pan-KDM5 inhibitor that can be used to study
H3K4 methylation biology.
RESULTS AND DISCUSSION
Discovery of KDOAM-25
We previously described 4-carboxy-2-triazolopyridines as se-
lective KDM2 inhibitors (England et al., 2014). In efforts to find
alternative scaffolds based on the 4-carboxypyridine core, a
range of compounds with a 2-aminomethyl group were synthe-
sized and tested for KDM inhibition. Aminomethylpyridines
such as KDOAM-1 showed a preference for the KDM4 and
KDM5 sub-families (Figure 1A), but we were unable to find ana-
logs with a potency in cellular immunofluorescence (IF) assays of
H3K36 and H3K4 demethylation. Hence, we were interested
when a patent application described very similar compounds
and reported potency in an almost identical cellular IF assay
(Labelle et al., 2014). In our hands, two of the compounds
described, named here KDOAM-20 and -21, showed low- and
sub-micromolar potency, respectively, in an H3K4me3 IF assay
overexpressing KDM5B, but also inhibited H3K9me3 demethy-
lation in accordance with its in vitro KDM4 activity (Figures S1A
and S1B). We considered it possible that KDOAM-21 may be
acting as an ester pro-drug akin to the KDM5/6 inhibitor, GSK-
J4 (Kruidenier et al., 2012). To our surprise, the ester KDOAM-
21 itself showed potent inhibition of KDM5B in vitro (Figure 1A).
However, KDOAM-20 was also a sub-micromolar inhibitor of
KDM4C, and KDOAM-21 could potentially be hydrolyzed to
KDOAM-20 in situ. Therefore, we sought to replace the ester of
KDOAM-20 with a less labile group such as an amide to retain
KDM5 potency and selectivity. There is some precedent for
this, as compound 16 in Bavetsias et al. (2016) is a weak
KDM4/5 inhibitor with some selectivity for KDM5A/B over
KDM4A/B (5- to 50-fold). The amides KDOAM-25, -28, and -29
were synthesized, and KDOAM-25 was shown to be the
most potent of the series with a KDM5B half maximal inhib-
itory concentration (IC50) of 19 nM and improved selectivity
over KDM4C.
We also investigated the biochemical inhibitory effect of
KDOAM-25 at different concentrations of the co-factor 2-OG
on KDM5B (Figure S2). The experiment indicated that the com-
pound acts a partial competitor of the co-substrate 2-OG, with
IC50 values increasing from 27 nM at 4 mM 2-OG, up to 558 nM
at 300 mM 2-OG.
With a potent KDM5B inhibitor available in the form of
KDOAM-25, we profiled it extensively for in vitro potency in all
our available JmjC KDM assays and assays for representative
2-OG-dependent oxygenases (Figure 1B and Table S1) using
AlphaScreen or MALDI-TOF enzymatic assays. KDOAM-25
was selective for the KDM5 sub-family with no inhibition below
4.8 mM for any of the other 2-OG oxygenases. KDOAM-25 was
also profiled in the CEREP express panel of 55 common off-tar-
gets but showed no inhibition at 10 mM (Table S5).
KDOAM-25 Binds to KDM5B in the 2-OG and
Substrate Sites
KDOAM-25 was crystallized in a JmjN-JmjC-linked construct of
KDM5B (Johansson et al., 2016) (Figure 2). The pose of the com-
pound was identical to the reported structure of KDOAM-20 in
Figure 1. Discovery of KDOAM-25
(A) KDOAM-21 is a weak KDM4/5 inhibitor. KDOAM-20 and -25 are potent and selective inhibitors of KDM5B over KDM4C.
(B) KDOAM-25 was tested against a panel of 15 2-OG oxygenases (black text) including a representative from each of the lysine demethylases sub-families (blue
branches). KDOAM-25 only inhibits the KDM5 sub-family members of KDM5A-D with potencies <100 nM (box).
*All IC50 values are an average of at least two independent determinations (Table S1);
zNot Determined.
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carboxylate binding pocket, Y425 is shifted from an H-donor
pose that interacts with the carboxylate of KDOAM-20 to allow
an inverse H-bond interaction with the carboxamide of
KDOAM-25. The shift of Y425 creates a cavity which is occupied
by a water molecule. The propensity for Y425 to adopt this alter-
native pose in KDM5B may explain why KDOAM-25 is selective
for KDM5 enzymes versus other KDMs that either form different
H-bonds to the 4-carboxypyridines (KDM2/3/6/7) or have a less
mobile homologous tyrosine (KDM4).KDOAM-25 Increases H3K4me3 Levels in HeLa Cells
The cellular activity of KDOAM-25 was assessed in an IF assay
by using an overexpression system, assessing the effect of
KDOAM-25 and related compounds on the ectopically overex-
pressed wild-type (WT) demethylases compared with their cata-
lytically dead mutants (MUT). As control we used a structurally
related inactive compound, KDOAM-32 (Figure S1D), which
is unable to coordinate the catalytic iron in the KDM5 active
sites (Figure S1 and Table S1). Consistent with its in vitro activity,
KDOAM-25 inhibited most potently KDM5B with an IC50Cell Chemical Biology 24, 371–380, March 16, 2017 373
Figure 2. Crystal Structure of KDOAM-25 Bound to KDM5B
(A) Surface representation of KDOAM-25 buried in the 2-OG pocket of KDM5B (PDB: 5A3N).
(B) KDOAM-25 (yellow sticks) binds to KDM5B (cyan sticks) as a bidentate metal chelator. The Mn(II) ion (purple sphere), which serves as the crystallographic
surrogate for the catalytic Fe(II), is held in the protein by one Asp and two His residues. Y425 is shifted to accommodate the carboxamide of KDOAM-25
compared with its pose (gray sticks) when binding KDOAM-20 (thin black sticks from PDB: 5A3T), which allows binding of an additional water molecule within the
pocket (KDOAM-25, green spheres; KDOAM-20, red spheres).
(C) Electron density (blue mesh from 2F0Fc map) of KDOAM-25 in the co-crystal structure with KDM5B. See Table S2 for crystallographic statistics.
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concentrations above 100 mM (Figure 3B), but showed no cellular
activity on any of the other tested JmjC family members (Fig-
ure 3C). At higher concentrations, all compounds showed
increased H3K4me3 levels for bothWT andMUT overexpressing
cells, indicating that the observed change in histone methylation
is likely a combination of inhibition of endogenous KDM5 as well
as the overexpressed enzyme, which made determination of an
accurate IC50 challenging.
KDOAM-25 also inhibited the activity of endogenous KDM5
demethylases with potencies similar to those seen in the overex-
pression assay (Figure S1C), and was found to be active in
increasing H3K4me3 levels, using chromatin immunoprecipita-
tion followed by parallel sequencing (ChIP-seq), at similar con-
centrations in human multiple myeloma cells (see below).
The exquisite biochemical selectivity profile of KDOAM-25 in-
dicates that the increase in the H3K4me3 mark is due to the in-
hibition of KDM5 enzymes. The other demethylase capable of
removing the H3K4me3 mark is KDM2B. KDM2B is structurally
and phylogenetically related to KDM2A (69% sequence similar-
ity), for which KDOAM-25 is a weak inhibitor with an IC50 of
4.4 mM (Table S1).
The higher concentration (60 mM) required for cellular activity
could be ascribed to different reasons: first to the partial compe-
tition with the co-factor 2-OG, the physiological intracellular con-
centrations of which could be up to micromolar levels (Thirstrup
et al., 2011); second to an estimated moderate-to-low cell
permeability of KDOAM25. A Caco-2 cell permeability assay
was used to evaluate the passive permeation through the cellular
membrane (Table S3), and KDOAM25 has shown values in the
low permeability region. Together these effects could explain
the partial loss of potency observed in the IF cell assay.
Although KDOAM-25 is a potent KDM5 inhibitor in vitro, we
could not rule out the possibility that some of the measured
cellular affects may be due to amide hydrolysis to give
KDOAM-20 in situ. For this reason we investigated the chemical374 Cell Chemical Biology 24, 371–380, March 16, 2017stability of KDOAM-25 in phosphate buffer and its biological sta-
bility in liver microsomes (Tables S3 and S4). Incubation of the
compound at 37C in PBS did not show any hydrolysis of the
amide after 24 hr, while the ester KDOAM-21 was partly hydro-
lyzed to the corresponding acid KDOAM-20 in 25% after the
same time. Similarly, incubation of KDOAM25 with different liver
microsomes (human, mouse, and rat) showed low intrinsic
clearance in all species (Table S3), indicating that the compound
is likely to have good biological stability within a cellular
environment.
Increased KDM5B Expression Is Associated with
Shorter Survival in Myeloma Patients and Ex Vivo
Inhibition with KDOAM-25 Results in Cell-Cycle Arrest
After having identified a selective and cell-active KDM5 inhibitor,
we then went on to employ this molecule in ex vivo experiments
in MM1S multiple myeloma cells. In line with various reports on
the oncogenic roles of the KDM5 enzymes (Kooistra and Helin,
2012), we found that the H3K4me3 demethylase KDM5B is
indeed a predictive factor in multiple myeloma. We performed
survival analysis using data from three separate, large clinical
datasets of newly diagnosed myeloma patients for whom the
level of (KDM5B) gene expression was measured at diagnosis.
Univariate analysis of the data from each trial indicated that
higher levels of expression of KDM5B were associated with
worse overall survival, with significantly shorter survival seen in
patients with expression in the upper quartile compared with
those having lower expression levels. A further multivariate anal-
ysis of the data from the Myeloma IX trial, for which the most
complete dataset was available, indicates that the highest quar-
tile ofKDM5B expression at diagnosis remains associated with a
statistically worse outcome compared with lower KDM5B
expression (p = 0.039). These data further highlight the impor-
tance of chromatin-modification mechanisms and, in particular,
the H3K4me3 demethylase KDM5B as an important factor in
multiple myeloma (Figure 4A).
Figure 3. KDOAM-25 Inhibits KDM5 Activity in Cells
(A) Half maximal effective concentration curves for KDOAM-25 against cells overexpressing FLAG-tagged KDM5B (left). Immunofluorescence assay showing
inhibition of KDM5B (WT)-mediated H3K4me3 demethylation by KDOAM-25, but no effect of the negative control compound KDOAM-32. Immunofluorescence
images showing HeLa cells stained with DAPI nuclear stain (blue), a specific antibody against H3K4me3 (green), and FLAG tag antibody (red) (right). Cells were
transfected with KDM5B and treated with the indicated inhibitors. Arrowheads indicate cells transfected with KDM5B-FLAG.
(B) KDM5A and KDM5C are inhibited to a lesser extent by KDOAM-25 in cells overexpressing the respective demethylase. ****p% 0.0001.
(C) KDOAM-25 has no effect on the histone substrates of the other KDM family members tested. No effect of any of the compounds is seen on any of the
overexpressing catalytically inactive mutants, MUT; dotted lines in (A), (B), and (C). IF was read after 24 hr of compound treatment. Data represents the average
and SE of at least 100 cells.
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Figure 4. KDM5B and KDOAM-25 in Multiple Myeloma Cells
(A) Increased histone H3K4me3 demethylase KDM5B expression is associated with shorter overall survival in multiple myeloma. Data from Affymetrix gene
expression analysis with linked survival was available from three large datasets of myeloma patients at diagnosis (Hovon65/GMMG-HD4 trial [n = 246, GEO:
GSE19784], MRCMyeloma IX trial [n = 259], Total Therapy 2 and 3 trials [n = 559, GEO: GSE2658]). Results for the probeset 201548_s_at (KDM5B) are shown as
Kaplan-Meier survival curves for patients comparing those with the highest quartile of expression (red) of KDM5B to all others (black).
(legend continued on next page)
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we screened the anti-proliferative effects of KDOAM-25 in the
MM1S multiple myeloma cell line. Using a fluorescent cell-
viability assay, we found that after a delay of 5–7 days,
KDOAM-25 was able to reduce the viability of MM1S cells with
an IC50 of 30 mM with little effect on cell viability after 3 days
(Figure 4B). KDOAM-25 treatment did not show the same
decrease in viability in a range of other multiple myeloma cells
or in a cell line derived from humanmesenchymal stem cells (Fig-
ure S3). KDOAM-25 treatment resulted in a G1 cell-cycle arrest
with an increased proportion of MM1S in G1 (p = 0.0286) and a
decrease of the proportion of cells in G2 without an increase in
the proportion of cells in the apoptotic sub-G1 phase (Figure 4C).
ChIP-seq was performed on MM1S cells treated with KDOAM-
25 to investigate the change in the distribution of H3K4me3
marks across the genome. When distribution of H3K4me3 was
measured following normalization to reads-per-million mapped
reads (RPM) there was little difference seen in the coverage of
H3K4me3 at either transcription start sites or across the totality
of all peaks called. We then employed the ChIP-Rx strategy to
enable quantification of the amount of pulled-down chromatin
(Orlando et al., 2014). Use of this spike-in quantification revealed
a global change in the level of H3K4me3, with approximately
twice as much H3K4me3 found in cells treated with KDOAM-
25 compared with the vehicle control (Figure 4D). As the increase
in H3K4me3 is global it is also observed at the transcription start
site of genes associated with endogenous ‘‘housekeeping’’
within the cell, such as b-actin (ACTB), pro-proliferative genes
such as cyclin D1 (CCND1), and anti-proliferative genes such
as cyclin-dependent kinase inhibitor 1a (CDKN1A) (Figure 4E).
SIGNIFICANCE
KDOAM-25 is a highly selective inhibitor of the KDM5 sub-
family of histone lysine demethylases with strongest activity
found against the catalytic domain of KDM5B. KDOAM-25
shows potent inhibition of the KDM5A-D enzymes in vitro
(<100 nM), and an expected corresponding increase in
H3K4me3 levels using IF detection in an ectopic expression
system in HeLa cells was seen with compound concentra-
tions in the two-digit micromolar range. Structure-based
design was used to generate KDOAM-25 without the need
for the previously reported ester pro-drugs. KDOAM-25 is
devoid of off-target activity on a CEREP express panel; it is
well tolerated in several cell lines, even at high concentra-
tions. Despite the fact that the compound cannot be consid-
ered as a chemical probe according to the SGC criteria
(cellular EC50 of 1 mM), due to its good stability, high selec-
tivity, and low cytotoxicity KDOAM-25 may be a useful tool,
although results should be considered carefully due to the
higher cellular EC50 of 50 mM. While there is no inhibition(B) Viability of MM1S when treated with KDOAM-25 as measured after 3, 5, or 7 d
normalized to DMSO control).
(C) KDOAM-25 significantly increases the proportion of cells in G1 and reduces
(D) Average coverage of H3K4me3 marks across transcription start sites (top) an
(left) or spike-in quantification (right) (mean of three independent experiments). K
(E) Coverage tracks of H3K4me3 normalized by spike-in quantification for three g
anti-proliferative gene CDKN1A.of any other KDM sub-families at this concentration,
other off-targets cannot be completely ruled out. Hence,
KDOAM-25 could help to investigate the biological roles of
the KDM5 enzymes in relevant cellular contexts. For
example, here we reported that KDOAM-25 shows an in-
verse relationship between KDM5B expression and overall
survival using data from three clinical multiple myeloma tri-
als, thus suggesting a potential application for KDM5B in-
hibitors in myeloma therapy. When human myeloma MM1S
cells were treated with KDOAM-25 at concentrations
consistent with inhibition of KDM5B-mediated H3K4me3
demethylation in myeloma cells, anti-proliferative effects
were observed with anticipated genome-wide increases in
H3K4me3 levels as demonstrated by quantitative ChIP-seq
experiments.
EXPERIMENTAL PROCEDURES
Compound Synthesis
KDOAM-20 (KDM5-C49) and KDOAM-21 (KDM5-C70) were purchased from
Xcessbio Biosciences.
KDOAM-25, -28, and -29 were prepared from KDOAM-21 via hydrolysis and
amide coupling. KDOAM-32 was prepared from methyl 5-(bromomethyl)-nic-
otinate. KDOAM-1 was prepared from diethyl pyridine-2,4-dicarboxylate. See
the Supplemental Information for full synthetic protocols.
Engineering of KDM5B Constructs for In Vitro Analysis
AKDM5B construct with selective deletion of the PHD and ARID domains, was
amplified from an OriGene cDNA clone, and cloned into a pFastBac-derived
vector (pFB-LIC-Bse), which contained a tobacco etch virus (TEV) protease-
cleavable N-terminal 6x-histidine tag. Successful cloning and correct
sequence of this construct were confirmed by Sanger sequencing.
Protein Expression and Purification
A KDM5B construct encoding regions Phe26-Ile770 was amplified from an
OriGene cDNA clone and cloned into a pFastBac-derived vector (pFB-LIC-
Bse) containing a TEV protease-cleavable N-terminal 6x-histidine tag. The re-
combinant KDM5B (residues 26–770) construct was expressed in Sf9 cells,
and generation of recombinant baculoviruses, insect cell culture, and infec-
tions was performed according to the manufacturer’s instructions (Invitrogen)
(Johansson et al., 2016). The cells were harvested 72 hr post infection and
lysed in a buffer containing 50mMHEPES (pH 7.5), 500mMNaCl, 10mM imid-
azole, 5% glycerol, 0.5 mM Tris(2-carboxyethy1)phosphine, and a proteinase
inhibitor cocktail (Calbiochem), and purified using nickel-affinity chromatog-
raphy using a stepwise gradient of imidazole. The eluted protein was then
incubated with TEV protease at 4C overnight, followed by size-exclusion
chromatography (Superdex 200). The TEV protease and uncleaved protein
were removed using nickel-affinity chromatography and protein was concen-
trated to 8.1 mg/mL and stored at 80C.
Protein Crystallization, X-Ray Data Collection, and Structure
Determination
Protein preparations were concentrated in Amicon concentrators to
8.1 mg/mL, and were subjected to crystallization experiments at 4C using
the sitting-drop vapor diffusion method. The protein was pre-incubated with
1 mM KDOAM-25 and 4 mM MnCl2 before the protein-compound mixtureays (mean ± SE of three independent experiments, each in quadruplicate and
the proportion in G2 without increasing the sub-G1 population. *p < 0.05.
d across all called-peaks (bottom) when normalized by either reads per million
DOAM-25 data shown in red and DMSO in blue.
enes, a ‘‘housekeeping’’ gene ACTB, a pro-proliferative gene cyclin D1 and an
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with KDOAM-25 in a drop consisting of 50 nL protein-compound mix
(8.1 mg/mL) and 100 nL of a precipitant consisting of 1.6 M Na/K phosphate,
0.1 M HEPES (pH 7.5), and 20 nL of KDM5B seeds of crystals obtained from
the same condition. Crystal was cryoprotected with mother liquor supple-
mented with 25% ethylene glycol before they were flash frozen in liquid nitro-
gen. The dataset was collected on beamline I02 at the Diamond Light Source.
The crystal belongs to P6522 diffracted to 2.0 A˚, and the dataset was pro-
cessed with XDS and scaled and merged with Aimless. The structure was
refined with a KDM5B model (51af). The protein-ligand model was further
improved by subsequent cycles of model building in Coot and refinement
with Phenix. The ligand library was generated with ELBOW. The quality of
the structure was assessed with MolProbity server.
Determination of Cellular H3K4me3 Levels
The human cervical carcinoma cell line HeLa was obtained from the American
Type Cultures Collection and maintained in Eagle’s minimal essential media
(Sigma-Aldrich) supplemented with 10% heat-inactivated fetal bovine serum
(Life Technologies). Full-length cDNA for KDM5B (JARID1B, Q9UGL1,
cDNA), KDM5C (JARID1C, P41229, IMAGE 5492114), KDM4B (JMJD2B,
O94953, gift from ICR), KDM4C (JMJD2C, Q9H3R0, 8143862), KDM3A
(JMJD1A, Q9Y4C1, 4823253), KDM2A (FBXL11, Q9Y2K7, 5534384), and
KDM6B (JMJD3, O15054, cDNA) were amplified by PCR from either an
MGC clone or a commercial cDNA source, or received as a gift from collabo-
rators and cloned into pDONR-221 vector using Gateway BP reaction produc-
ing Gateway entry clones.
To produce catalytically inactive KDMs, residues involved in iron coordi-
nation were mutated to alanine (KDM5B H499A/E501A, KDM5C H513A/
E515A, KDM4B H189A/E191A, KDM4C H190A/E192A, KDM3A H1120Y,
KDM2A H212A/D214A, and KDM6B H1390/E1392). Mutations were intro-
duced into full-length KDM Gateway entry clones using 15 cycles of the
QuikChange II PCR protocol (Agilent Technologies). Mammalian expression
constructs encoding N-terminal 3*FLAG were constructed using the
Gateway LR recombination reaction between pCDNA5-FRT/TO-3FLAG
destination vector (Lambert et al., 2014) and the WT or mutated KDM
Gateway entry clone. Experimental details describing the overexpression
KDM IF assay have been published previously (Bavetsias et al., 2016; Hop-
kinson et al., 2013).
In brief, cells were transiently transfectedwith either the FLAG-taggedWT or
mutant demethylase described above, using Lipofectamine 2000 (Life Tech-
nologies). Four hours after transfection the cells were treated with serial dilu-
tions of compound for 24 hr. The cells were subsequently fixed and stained
with an anti-FLAG antibody (Sigma F3165) as well as an anti-methylated his-
tone antibody (H3K4me3 Diagenode C15410003, H3K9me2 Abcam ab1220,
H3K9me3 Abcam ab8898, H3K27me3 Millipore 07–449, or H3K36me2 Active
Motif 61019). The secondary antibodies were labeled with either Alexa Fluor
488 or 568 (Life Technologies). Image acquisition was conducted using the
Operetta High Content Imaging System (PerkinElmer) and image analysis
was performed with the Columbus software (PerkinElmer). After the DAPI-
stained nuclei were automatically identified, a minimum threshold for anti-
FLAG intensity was set so that only cells highly expressing the demethylase
were analyzed. Assays assessing the endogenous H3K4me3 methyl mark
changes were performed accordingly without overexpressing KDM5 after
compounds treatment for 48 hr.
Sf9 Genome Sequencing
Sf9 cells, derived from the fall armyworm (Spodoptera frugiperda), routinely
used for protein expression within the laboratory, were used. The genomic
DNA from 107 cells was extracted using the Quick-gDNA MiniPrep Kit (Zymo
Research) according to the manufacturer’s instruction and sonicated to an
average size of approximately 350 bp. Illumina-compatible paired-end
libraries were constructed using the NebNext Ultra DNA Kit (NEB) and
sequenced on a NextSeq500 (Illumina) with 83 bp reads in both directions.
One hundred million pairs of reads were error corrected using Fiona (Schulz
et al., 2014) prior to de novo genome assembly using Spades (Bankevich
et al., 2012). This process was repeated using a separate 100 million pair
read, and a consensus assembly between the two de novo assemblies
was created using AMOS and MUMmer. For use in quantitative ChIP, the378 Cell Chemical Biology 24, 371–380, March 16, 2017assembled contigs were concatenated to the human genome (hg38) to
generate a merged genome, and indexes for aligning were built with Bowtie.
ChIP-Seq
MM1S cells (107) were treated with either 50 mM KDOAM-25 or DMSO for
7 days. Immediately prior to fixation in 1% formaldehyde, three million sf9 cells
were added to each sample. Cells were fixed for 8 min at room temperature,
lysed, and sonicated on a Bioruptor Pico for 3 repeats of 10 cycles of 30 s
on/30 s off. The sonicated lysates were incubated for 1 hr at 4C with pre-
blocked protein A Sepharose beads, prior to overnight incubation with 1 mg
of anti-H3K4me3 antibody (Millipore cat no. 07–473 lot no. 2207281). Pre-
blocked Sepharose beads were added for 1 hr, the beads washed, and DNA
was eluted followed by Proteinase K digestion. Libraries were constructed us-
ing the NebNext Ultra DAN Kit (NEB) and sequenced on an Illumina NextSeq
500 platform. Libraries were also generated for the input of each condition
and sequenced in a similar manner.
Data Processing of ChIP-Seq
Sequencing reads were aligned to the concatenated human/sf9 genome
generated earlier using Bowtie (version 1.1.2), allowing only reads that
matched uniquely to one location. The number of reads mapping to the human
and sf9 genomes separately in each condition was calculated. The number of
sf9 reads-per-million total aligned reads was calculated for each pull-down
condition and corrected according to the percentage of sf9 reads in the corre-
sponding input samples. A scaling factor for normalization was then calculated
for each pull-down based on the reciprocal of the corrected sf9 reads per
million for each sample.
The aligned Bam files were converted to bedGraph files using BedTools for
each strand of each sample using the scaling factor derived earlier. Homer
v4.8 was used to read the produced bedGraphs for each sample and create
a Tag Directory for each sample that was used for subsequent calculations
of coverage. Peaks were called using macs2 with the ‘‘–broad option’’ and
the gapped-peaks called used for downstream analysis.
Coverage at the transcription start site and across each peakwas calculated
for each condition using Homer for both reads normalized on a reads-per-
million basis and those normalized with the Sf9 spike in and an average taken
to produce the values plotted.
Measurement of Cell Viability
MM1S myeloma cells were cultured in RMPI with 10% heat-inactivated FCS
and 2 mM glutamine under standard conditions. A total of 5 3 105 cells per
well was seeded into a 96-well plate and treated with a range of doses of
KDOAM-25: from 50 mM to approximately 10 nM for 7 days. Viability was
measured using PrestoBlue reagent and normalized to a vehicle control.
Data were plotted and IC50 values were calculated in Prism (v5.1).
Survival Curves from Clinical Trials
Gene expression profiling was performed on the CD138-selected plasma cells
from newly diagnosed multiple myeloma patients. Data from expression anal-
ysis with linked survival was available for three large trials of myeloma patients
at diagnosis. These are the MRC Myeloma IX trial (n = 259), the Hovon65/
GMMG-HD4 trial (n = 246), and the Total Therapy 2 and 3 trials (n = 559).
Results for the Affymetrix probe 201548_s_at were used. Kaplan-Meier sur-
vival curves for patients comparing high expressors of KDM5B with all others
were plotted.
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